Computer-aided image-enhanced endoscopy can predict the nature of colorectal polyps with over 90% accuracy. This technology uses artificial intelligence (AI) to analyze video recordings of polyps, learning to make diagnoses in real-time. This means that doctors can get immediate predictions about small polyps during the procedure, reducing the need for separate pathology exams and saving costs, ultimately improving patient care. Human and AI interactions are complex and a framework to reap synergistic effects CADx systems when used by humans to harness optimal performance needs to be established. AI solutions in medicine are usually developed to be used as assistive devices, however, then they rely on humans to correct AI errors. Optical polyp diagnosis is a complex task. Non experts usually achieve diagnostic accuracy in 70-80%. CADx systems have a similar diagnostic accuracy when used autonomously. Clinical evaluation of CADx systems showed that CADx assisted OD performs equally to the operator performance when using non CADx assisted OD. To harness a benefit of clinical CADx implementation we would have to find a way that synergies between human and CADx come into play to eliminate cases in which CADx assisted and/ or human OD results in low diagnostic accuracy and also addresses the problem of serrated polyp recognition.
Our study hypothesis is that for CADx implementation, instead of using the high/low confidence framework, identifying cases with suboptimal diagnostic accuracy could be facilitated through identifying cases in which CADx and endoscopist disagreed in their diagnosis. Eliminating such cases might separate out cases with low accuracy when using CADx assisted OD. Since endoscopists have a high sensitivity but low specificity for serrated polyp OD, this framework will also allow us to implement a strategy to adequately manage serrated polyps found in the cohort.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
540
The CADx system will be used to predict the histopathology of the polyp detected.
Ghislaine Ahoua
Montreal, Quebec, Canada
Accuracy of optical diagnosis, for polyps 1-5mm, compared with an agreed upon CADx-assisted diagnosis
Accuracy of optical diagnosis, for polyps 1-5mm, compared with an agreed upon CADx-assisted diagnosis , when histopathology results are used as the reference
Time frame: up to 100 weeks
Accuracy of optical diagnosis, for polyps 1-10mm, compared with an agreed upon CADx-assisted diagnosis
Accuracy of optical diagnosis, for polyps 1-10mm, compared with an agreed upon CADx-assisted diagnosis, when histopathology results are used as the reference
Time frame: up to 100 weeks
Test characteristics, including recall, specificity, positive and negative predictive values (PPV/NPV), and particularly the NPV of rectosigmoid neoplastic polyps.
A ≥90% NPV will be used as a quality benchmark for a strategy to not resect such diminutive polyps.
Time frame: up to 100 weeks
Agreement of surveillance interval recommendations of AI-A and AI-H compared with the pathology-based recommendations
For surveillance interval assignment, the pathology results of concomitant polyps \>5 mm (including multiple concomitant polyps of all sizes and histology) will be considered when calculating the surveillance interval recommendation. Surveillance recommendations will be based on the 2020 United States Multi Society Task Force Guidelines as is current standard of practice at our center.
Time frame: up to 100 weeks
Proportion of patients for whom an immediate surveillance recommendation can be directly provided for each approach, and how often histopathology-based polyp examination would have been avoided.
The potential cost-effectiveness of OD (either approaches) will be evaluated using the measured described above.
Time frame: up to 100 weeks
Variability of OD (AI-A and AI-H) across participating endoscopists.
Each participating endoscopist will conduct a similar number of optical diagnoses to assess endoscopist-related factors.
Time frame: up to 100 weeks
Cost-effectiveness of OD ((AI-A and AI-H)
A cost-effectiveness model will be applied to better quantify costs and understand cost impact including key cost drivers when generalized to a broader screening population.
Time frame: up to 100 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.